Blick ins Buch

Acceptable Risk in Biomedical Research

European Perspectives

Sigmund Simonsen (Autor)

Buch | Hardcover

296 Seiten

2012 | 2012
Springer (Verlag)
978-94-007-2677-2 (ISBN)

Lese- und Medienproben

Blick ins Buch (midvox)

Artikel merken

This book is the first major work that addresses a core question in biomedical research: the question of acceptable risk. It is a relevant work for lawyers and ethicists, and the practical approach makes a valuable tool for researchers and members of research ethics committees supervising biomedical research.

This book is the first major work that addresses a core question in biomedical research: the question of acceptable risk. The acceptable level of risks is regulated by the requirement of proportionality in biomedical research law, which state that the risk and burden to the participant must be in proportion to potential benefits to the participant, society or science.

This investigation addresses research on healthy volunteers, children, vulnerable subjects, and includes placebo controlled clinical trials. It represents a major contribution towards clarifying the most central, but also the most controversial and complex issue in biomedical research law and bioethics. The EU Clinical Trial Directive, the Council of Europe’s Oviedo Convention (and its Additional Protocol), and national regulation in member states are covered. It is a relevant work for lawyers and ethicists, and the practical approach makes a valuable tool for researchers and members of research ethics committees supervising biomedical research.

1.      Introduction.-

2.      Method and material.-

3.      Initial conceptual clarifications.-

4.      Origins of the requirement of proportionality.-

5.      The purpose of the requirement of proportionality.-

6.      Introduction: Part II .-

7.      Which risks, burdens and potential benefits are relevant?.-

8.      How to estimate risks, burdens, and potential benefits.-

9.      The requirement of proportionality – initial clarifications.-

10. Therapeutic research.-

11. Nontherapeutic research.-

12. Nontherapeutic research on “vulnerable” participants.-

13. Non-interference with necessary clinical interventions and the no harm rule.-

14. Especially on randomised clinical trials, including placebo controlled clinical trials.-

15. Acceptable Risks and Burdens to Others than the Participant.-

16. Later developments during the course of the research.-

17. Legal effects of the requirement of proportionality.-

18. Summary of results.-

19. Recommendations.-

20. Perspectives.-

21. Appendix.-.

Reihe/Serie	"International Library of Ethics, Law, and the New Medicine " ; 50
Zusatzinfo	XVI, 296 p.
Verlagsort	Dordrecht
Sprache	englisch
Maße	155 x 235 mm
Themenwelt	Geisteswissenschaften ► Philosophie ► Allgemeines / Lexika
	Medizin / Pharmazie
	Naturwissenschaften ► Biologie
	Recht / Steuern ► EU / Internationales Recht
	Recht / Steuern ► Privatrecht / Bürgerliches Recht ► Medizinrecht
	Sozialwissenschaften ► Soziologie
Schlagworte	acceptable risk • biomedical research • biomedical research law • clinical trial directive • clinical trials and placebo use • Criminal Liability • estimating risks • human experimentation • Oviedo convention • patient autonomy • placebo clinical trials • potential benefit and risk • randomized clinical trials • Requirement of Proportionality • research benefits and risks • risk assessment • the Nuremberg code • vulnerable research participants
ISBN-10	94-007-2677-5 / 9400726775
ISBN-13	978-94-007-2677-2 / 9789400726772
Zustand	Neuware